



22nd December 2016

## BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
<b>Indices</b>			
Dow Jones	19941.96	-0.16%	+14.44%
S&P 500	2265.18	-0.25%	+10.82%
Nasdaq	5471.43	-0.23%	+9.27%
Nikkei	19444.49	-0.26%	+2.16%
Stoxx 600	360.556	-0.21%	-1.44%
CAC 40	4833.82	-0.33%	+4.24%
<b>Oil /Gold</b>			
Crude WTI	51.39	-1.74%	+38.15%
Gold (once)	1131.86	+0.39%	+6.54%
<b>Currencies/Rates</b>			
EUR/USD	1.0433	+0.53%	-3.96%
EUR/CHF	1.07055	+0.22%	-1.55%
German 10 years	0.156	-13.66%	-75.49%
French 10 years	0.701	-1.86%	-28.58%
Euribor	-	+-%	+-%

### Economic releases :

Date	
22nd-Dec	14h30 US Durable Goods Orders 14h30 US Initial Jobless Claims 16h00 US Personal Consumption Exp.

### Upcoming BG events :

### Recent reports :

Date	
13th-Dec	Construction - Paris Reverse Roadshow feedback
7th-Dec	Brewers : Our takeaways from the Consumer Conference
5th-Dec	TAVI is VITAL
2nd-Dec	FD-SOI: forbidden fruit of the industry and market
29th-Nov	Morphosys We want MORE! (Fair Value EUR65 BUY)
28th-Nov	Fashion E-Commerce: Serving Consumers not Uberising Them! Coverage initiation of ZALANDO, YOOX, H&M,

List of our Reco & Fair Value : Please click here to download



### HEINEKEN

**BUY, Fair Value EUR83 (+16%)**

#### Recent trading in line with expectations

We believe that European operations were under slightly more pressure in Q4, but that should be offset by better African trends (easy comps), whereas the trends in both Americas and Asia Pacific remained strong. For 2016, we look for organic revenue growth of 2.3% and organic operating profit growth of 5.0%. This would be a marked slowdown on the 4.7% and 12.6% that the company delivered for H1 2016, due to tough comps in Europe in the second part of the year and increasing currency headwinds. For the full year, we look for a 40bps margin improvement to 17.2% from 16.8%.

### PHARMACEUTICALS

#### ACE910's Phase III results are positive as expected, but more detail needed

As expected, ROG's Phase III evaluating ACE910 as a prophylaxis in haemophilia A with inhibitors met its primary endpoint (reduction in the number of bleeds over time); and so far, no additional thromboembolic events or thrombotic microangiopathies (TMA) have been reported... Having said that, we lack detailed data and especially when it comes to the reasons behind these TMAs. Consequently, we make no changes to our ratings/fair values on ROG, SHP, GFS, NOVO and SOBI.

### In brief...

#### ACCORHOTELS, New lease contract portfolio restructuring in Australia

the agreement concerns a portfolio of 31 hotels (4 097 rooms), owned by a subsidiary of Abu Dhabi Investment Authority (ADIA) and managed by AccorHotels under lease contract.

#### ALTICE, Altice sells its Belgium and Luxembourg business

Altice announced today that it has reached an agreement with Telenet to sell its Belgium and Luxembourg business.

Food & Beverages

**Heineken**

Price EUR71.28

Recent trading in line with expectations

Fair Value EUR83 (+16%)

**BUY**

Bloomberg	HEIA.NA
Reuters	HEIN.AS
12-month High / Low (EUR)	84.4 / 68.0
Market Cap (EUR)	41,057
Ev (BG Estimates) (EUR)	54,601
Avg. 6m daily volume (000)	731.2
3y EPS CAGR	5.6%

We believe that European operations were under slightly more pressure in Q4, but that should be offset by better African trends (easy comps), whereas the trends in both Americas and Asia Pacific remained strong. For 2016, we look for organic revenue growth of 2.3% and organic operating profit growth of 5.0%. This would be a marked slowdown on the 4.7% and 12.6% that the company delivered for H1 2016, due to tough comps in Europe in the second part of the year and increasing currency headwinds. For the full year, we look for a 40bps margin improvement to 17.2% from 16.8%.

	1 M	3 M	6 M	31/12/15
Absolute perf.	0.6%	-8.6%	-11.8%	-9.5%
Food & Bev.	4.0%	-5.7%	-3.8%	-6.0%
DJ Stoxx 600	6.0%	5.3%	6.0%	-1.4%

We had a pre-close call with Heineken which, on the basis of the recent October and November figures, confirmed that for 2016 the company expects to deliver organic revenue and profit growth. Margin expansion should be in line with the medium-term margin guidance of a year-on-year improvement in operating profit margin of around 40bps. This takes into account the tough comparatives and increasing currency headwinds in the second half of the year.

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	20,511	20,579	21,019	21,581
% change		0.3%	2.1%	2.7%
EBITDA	4,975	5,054	5,331	5,645
EBIT	3,381	3,460	3,613	3,816
% change		2.3%	4.4%	5.6%
Net income	2,048	2,084	2,244	2,412
% change		1.8%	7.7%	7.5%

**ANALYSIS**

We believe that European operations were under slightly more pressure in Q4, but that should be offset by better African trends (easy comps), whereas the trends in both Americas and Asia Pacific remained strong. For 2016, we look for organic revenue growth of 2.3% and organic operating profit growth of 5.0%.

	2015	2016e	2017e	2018e
Operating margin	16.5	16.8	17.2	17.7
Net margin	10.0	10.1	10.7	11.2
ROE	15.1	14.3	14.2	14.1
ROCE	8.2	8.0	8.4	8.9
Gearing	86.0	75.3	62.8	50.6

After Heineken surprised in Q3 with a strong 0.6% organic volume growth in Europe, Q4 seems set to come in weaker (even in negative territory) with soft demand in the UK, Poland and the Netherlands. For the full year, we estimate the company can achieve organic volume growth of 1.5% and deflation pressures to balance the ongoing premiumisation delivering very weak price/mix.

(EUR)	2015	2016e	2017e	2018e
EPS	3.57	3.64	3.92	4.21
% change	-	1.8%	7.7%	7.5%
P/E	19.9x	19.6x	18.2x	16.9x
FCF yield (%)	4.1%	4.0%	5.3%	6.0%
Dividends (EUR)	1.11	1.08	1.17	1.25
Div yield (%)	1.6%	1.5%	1.6%	1.8%
EV/Sales	2.7x	2.7x	2.5x	2.4x
EV/EBITDA	11.2x	10.8x	9.9x	9.1x
EV/EBIT	16.4x	15.8x	14.6x	13.4x

In Africa, the company enjoys easy comps, but the underlying conditions in Nigeria, DRC, and Egypt remain challenging. A price increase in Nigeria in September was immediately followed by ABI/SABMiller and Diageo who do not have the same scale as Heineken (and should be close to loss making). For 2016, we expect flattish organic revenue growth but because most of the imported costs are in USD (about 60% of COS), we look for a significant 470bps margin pressure.

In Americas and Asia, the positive trends from first half and Q3 seem to continue. In Asia the momentum is strongly driven by Vietnam and Cambodia, with Indonesia and China a little softer. Overall we expect organic volume growth in Asia Pacific of 14% which should create leverage for operating profit growth and we look for margin expansion of 180bps. In the Americas the slightly disappointing message keeps coming from the US where volumes were down as the growth in Tecate did not offset the decline in Heineken Light volumes. But in Mexico volume growth seems to continue at high single digit and the Heineken brand continued to grow double digit in Brazil (although total volumes declined mid-single digit). On Brazil, Heineken does warn for unseasonable cold weather on top of the tough trading conditions.

**VALUATION**

We leave our DCF based fair value of EUR88 unchanged and base it on a risk free rate of 1.6% and a risk premium of 7%.

**NEXT CATALYSTS**

14 February 2017: full year results

[Click here to download](#)



**Analyst :**  
 Nikolaas Faes  
 33(0) 6 11 12 44 44  
 nfaes@bryangarnier.com

**Sector Team :**  
 Loïc Morvan  
 Antoine Parison  
 Cédric Rossi  
 Virginie Roumage

Sector View

**Pharmaceuticals**

ACE910's Phase III results are positive as expected, but more detail needed

	1 M	3 M	6 M	31/12/15
Healthcare	3.3%	-4.4%	-1.9%	-11.1%
DJ Stoxx 600	6.0%	5.3%	6.0%	-1.4%

\*Stoxx Sector Indices

As expected, ROG's Phase III evaluating ACE910 as a prophylaxis in haemophilia A with inhibitors met its primary endpoint (reduction in the number of bleeds over time); and so far, no additional thromboembolic events or thrombotic microangiopathies (TMA) have been reported... Having said that, we lack detailed data and especially when it comes to the reasons behind these TMAs. Consequently, we make no changes to our ratings/fair values on ROG, SHP, GFS, NOVO and SOBI.

Companies covered

<b>ACTELION</b>	<b>BUY</b>	<b>CHF194</b>
Last Price	CHF215	Market Cap. CHF23,169m
<b>ASTRAZENECA</b>	<b>BUY</b>	<b>5100p</b>
Last Price	4312.5p	Market Cap. GBP54,555m
<b>BAYER</b>	<b>NEUTRAL</b>	<b>EUR98</b>
Last Price	EUR98.7	Market Cap. EUR81,620m
<b>GLAXOSMITHKLINE</b>	<b>BUY</b>	<b>1930p</b>
Last Price	1528p	Market Cap. GBP75,025m
<b>GRIFOLS</b>	<b>NEUTRAL</b>	<b>EUR21</b>
Last Price	EUR18.46	Market Cap. EUR11,789m
<b>IPSEN</b>	<b>BUY</b>	<b>EUR72</b>
Last Price	EUR68.17	Market Cap. EUR5,684m
<b>NOVARTIS</b>	<b>NEUTRAL</b>	<b>CHF81</b>
Last Price	CHF73.7	Market Cap. CHF193,618m
<b>NOVO NORDISK</b>	<b>NEUTRAL</b>	<b>DKK270</b>
Last Price	DKK253.5	Market Cap. DKK510,185m
<b>ROCHE HOLDING</b>	<b>BUY</b>	<b>CHF285</b>
Last Price	CHF233.2	Market Cap. CHF163,838m
<b>SANOFI</b>	<b>NEUTRAL</b>	<b>EUR83</b>
Last Price	EUR75.2	Market Cap. EUR97,072m
<b>SHIRE PLC</b>	<b>BUY</b>	<b>6800p</b>
Last Price	4558p	Market Cap. GBP41,205m
<b>SOBI</b>	<b>SELL</b>	<b>SEK90</b>
Last Price	SEK104.8	Market Cap. SEK28,337m
<b>UCB</b>	<b>NEUTRAL</b>	<b>EUR80</b>
Last Price	EUR60.15	Market Cap. EUR11,700m

ANALYSIS

- **ROG's ACE910: successful first Phase III.** As we expected, ROG's Phase III study evaluating ACE910/Emicizumab in Haemophilia A with inhibitors met its primary endpoint (statistically significant reduction in the number of bleeds over time in people treated with ACE910 prophylaxis compared to those receiving no prophylactic treatment) along with different key secondary ones. Safety-wise, the compound was generally well-tolerated and no additional thromboembolic events or thrombotic microangiopathies (TMA) have been reported.
- **But more detail needed to fully appreciate its potential.** Unfortunately, we lack details about 1/ the exact reduction in the number of bleeding events (knowing that the Phase I showed an impressive decrease in median ABR compared to baseline, irrespectively of the inhibitor status – see Fig. below for further details); 2/ the mechanistic reasons behind the two TMA. The latter point is of essence in our view (is it related to the monoclonal antibody nature of the compound and a complement hyperactivation, for example?); 3/ the eventual incidence of neutralizing/non-neutralizing antibodies against ACE910.

ACE910's Efficacy profile in a small Phase I – Haemophilia A with and without inhibitors

Treatment Arm	Bleeding events	Median ABR	Median ABR	Median ABR
		Baseline	12 week follow-up	LT follow-up
0.3 mg/kg emicizumab (n=6)	All bleeds	32.5	4.4	1.4
	Joint bleeds	27.4	4.3	1.1
1 mg/kg emicizumab (n=6)	All bleeds	18.3	0	0.2
	Joint bleeds	15.2	0	0.2
3 mg/kg emicizumab (n=6)	All bleeds	15.2	0	0
	Joint bleeds	9.1	0	0


- **We do not expect substantial stock reactions this morning.** This is obviously good news for ROG as ACE910 is one of these key growth drivers/lines of defence against biosimilars' advent in the next few years... but the stock is very unlikely to strongly outperform before the readout of APHINITY. On the other hand, we lack materials to draw firm conclusions regarding its potential impact on the different companies exposed to the inhibitor segment (and especially on SHP).

VALUATION

- We stick to our respective ratings/fair values on ROG, SHP, NOVO, GFS and SOBI pending more details from this Phase III.
- As a reminder, 1/ we see a peak sales of c.USD1.5Bn for ACE910 in the inhibitor segment (vs USD0.6Bn when it comes to the non-inhibitor one, given our uncertainties on its LT safety profile); 2/ we expect a steep decline in both SHP's Feiba and NOVO's NovoSeven sales from 2018.

NEXT CATALYSTS

2017: presentation of detailed data at a scientific congress.



**Analyst :**  
 Team Pharma  
 33(0) 1 56 68 75 33  
 healthcare@bryangarnier.com

**Sector Team :**  
 Mickael Chane Du  
 Eric Le Berrigaud  
 Marion Levi  
 Hugo Solvet

## Hotels

**AccorHotels**

Price EUR35.89

**New lease contract portfolio restructuring in Australia**

Fair Value EUR42 (+17%)

BUY

Bloomberg	AC FP
Reuters	ACCP.PA
12-month High / Low (EUR)	41.0 / 30.0
Market Cap (EURm)	10,218
Avg. 6m daily volume (000)	1 152

	1 M	3 M	6 M	31/12/15
Absolute perf.	6.8%	2.1%	-6.1%	-10.3%
Travel&Leisure	3.6%	3.3%	-3.0%	-11.9%
DJ Stoxx 600	6.0%	5.3%	6.0%	-1.4%

	2015	2016e	2017e	2018e
P/E	22.5x	21.5x	17.5x	15.3x
Div yield (%)	2.8%	2.8%	3.1%	3.2%

**ANALYSIS**

- Management announced yesterday evening a new restructuring of lease contract in Australia. In fact, the agreement concerns a portfolio of 31 hotels (4 097 rooms), owned by a subsidiary of Abu Dhabi Investment Authority (ADIA) and managed by AccorHotels under lease contract.
- Under the restructuring, AccorHotels will convert 15 lease contracts (triple-net) into 50-year management contracts, extend the management term of 1 hotel also to 50 years and will acquire the remaining 15 hotels for a total of AUD\$200m (EUR137m).
- Management announced that the deal will be accretive to group 2017 EBIT, but provided no detail or precise numbers. As of 30<sup>th</sup> June 2016 (before FRHI deal) AccorHotels operated 207 hotels in Australia with a total of 27 355 rooms representing 5.2% of the group total.

**VALUATION**

- At the current share price, the stock is trading 9.9x EV/EBITDA 2016e and 8.5x 2017e.

**NEXT CATALYSTS**

- FY results on 22<sup>nd</sup> February

[Click here to download](#)Bruno de La Rochebrochard, [bdelarochebrochard@bryangarnier.com](mailto:bdelarochebrochard@bryangarnier.com)

TMT

**Altice**

Price EUR18.83

**Altice sells its Belgium and Luxembourg business**

Fair Value EUR19 (+1%)

BUY

Bloomberg	ATC NA
Reuters	ATCA.AS
12-month High / Low (EUR)	18.9 / 11.2
Market Cap (EURm)	23,159
Avg. 6m daily volume (000)	1 673

	1 M	3 M	6 M	31/12/15
Absolute perf.	19.6%	14.1%	33.7%	42.1%
Telecom	6.2%	-1.6%	-4.8%	-15.9%
DJ Stoxx 600	6.0%	5.3%	6.0%	-1.4%

	2015	2016e	2017e	2018e
P/E	NS	NS	38.7x	14.6x
Div yield (%)	NM	NM	NM	NM

**ANALYSIS**

- Altice announced today that it has reached an agreement with **Telenet** to sell its **Belgium and Luxembourg business**. The transaction values the business at an enterprise value of **EUR400m**, ie at **8.8x 2016e adjusted EBITDA**, and at **6.5x 2016e EBITDA** when adjusted for Telenet's projected annual run-rate synergies of **EUR16m** by 2021.
- We think the **price is very good** for Altice, showing Patrick Drahi's **know-how** not only in buying companies, but also in selling them. Besides the valuation, as we had already mentioned, we think selling **non-strategic assets** to help **deleverage and focus** on major activities in the group is an **appropriate strategy**. As a reminder, Belgium and Luxembourg are about **0.5%** of Altice Group total adjusted 2016e EBITDA. Thanks to this transaction, we believe Altice net debt as end of 2016 should be around **EUR48bn**.
- The transaction will be subject to **regulatory review** by the Belgian authorities. Telenet says it is **confident** it should receive approval within a few months. We believe there should not be any major regulatory issues in this deal which will mainly reinforce Telenet's position in Brussels.

**VALUATION**

- We stick to our Fair Value of EUR 19, with a Buy recommendation.

**NEXT CATALYSTS**

- Full year 2016 results expected mid-march 2017.

[Click here to download](#)Thomas Coudry, [tcoudry@bryangarnier.com](mailto:tcoudry@bryangarnier.com)

## BG's Wake Up Call

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

### Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

### Distribution of stock ratings

BUY ratings 54.3%

NEUTRAL ratings 35.8%

SELL ratings 9.9%

## Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/Infrastructures/Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Automotive & Parts		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

London	Paris	New York	Munich
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle Prudential et de Résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany <b>+49 89 2422 62 11</b>



## BRYAN, GARNIER & CO

### Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

### Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

#### Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

#### Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

#### Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

#### Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....